Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of LY03020 in Healthy Adults and Stable Schizophrenia
NCT07230652Phase 1Recruiting
- Sponsor
- Luye Pharma Group
- Start
- Aug 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in schizophrenia comparing LY03020 with Placebo (2 arms). Primary endpoint: Number of participants with adverse events and serious adverse events at Day 11. Started Aug 2025; status: recruiting.
02
Drugs
lpm787000048 maleate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07230652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07230652.